• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis

byMinjee Kim
April 14, 2022
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. This trial demonstrated noninferiority of daprodustat to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease starting incident analysis.

2. The safety profile was similar between daprodustat and darbepoetin alfa in this short-term study.

Evidence Rating Level: 1 (Excellent)

Study Rundown: In the treatment of patients with anemia of chronic kidney disease (CKD) on incident dialysis (ID), there is limited research examining the comparative efficacy and safety of conventional erythropoiesis-stimulating agents (ESAs), such as darbepoetin alfa and the novel hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), such as daprodustat. This randomized clinical trial (ASCEND-ID) assessed the efficacy and safety of oral daprodustat compared to darbepoetin alfa for 52 weeks in patients on ID. The primary endpoint was noninferiority of daprodustat compared to darbepoetin alfa (noninferiority margin, −0.75 g/dL) assessed via the mean change in hemoglobin (Hb) concentration from baseline to evaluation period (weeks 28-52). The secondary endpoint was the mean monthly intravenous (IV) iron dose from baseline to week 52. Among 312 patients with CKD on ID, daprodustat was noninferior to darbepoetin alfa in the treatment of anemia of CKD. Furthermore, the safety profile and monthly IV iron usage was similar between treatment groups in this short-term study. Long-term validation trials are required in the future to confirm daprodustat as a potential oral alternative to conventional ESAs for patients with CKD who are starting dialysis. A limitation of this study was the short study period and small sample size, limiting the evaluation of long-term effects and safety associated with daprodustat.

Click to read the study in JAMA Internal Medicine

Relevant Reading: Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease

RELATED REPORTS

Empagliflozin use is associated with slower progression of chronic kidney disease

DART improves treatment decision-making for patients with chronic kidney disease

Ferric derisomaltose may reduce heart failure-related hospitalizations

In-Depth [randomized clinical trial]: This multicenter trial included 312 patients (median [IQR] age, 55 [45-65] years; 194 [62%] male) with CKD randomized 1:1 to daprodustat (N =157) or darbepoetin alfa (N = 155) from May 2017 to September 2020 across 90 centers in 14 countries. Eligibility criteria included patients planning to start dialysis within 6 weeks from screening or had started treatment within 90 days before randomization, screening and random Hb concentration of 8.0-10.5 g/dL and 8.0-11.0 g/dL respectively, ESA-naive or previous limited ESA treatment, and iron-replete. The mean (SD) Hb concentration was 10.5 (1.0) g/dL and 10.6 (0.9) g/dL for daprodustat and darbepoetin alfa respectively (adjusted mean treatment difference, −0.10 g/dL [95% CI, −0.34 to 0.14 g/dL]), indicating noninferiority. Overall, both treatments reduced the mean monthly IV iron use, however, daprodustat was not superior compared with darbepoetin alfa in reducing monthly IV iron use (adjusted mean treatment difference, 19.4mg [95%CI, –11.0 to 49.9mg]). Adverse event rates were 76% vs 72% for daprodustat and darbepoetin alfa respectively.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: anemiaanemia of chronic kidney diseaseanemia of CKDASCEND-IDCKDdaprodustatDarbepoetin alfadialysishemoglobinprolyl hydroxylase inhibitor
Previous Post

Fewer hospital admissions and death were seen with SARS-CoV-2 Delta (B.1.617.2) compared to Omicron (B.1.1.529) variant infections

Next Post

Wellness Check: Sleep

RelatedReports

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
American College of Physicians releases principles to guide patient partnership in health care
Chronic Disease

DART improves treatment decision-making for patients with chronic kidney disease

January 9, 2023
No association found between length of storage for transfused red blood cells and patient mortality
Cardiology

Ferric derisomaltose may reduce heart failure-related hospitalizations

December 27, 2022
2 Minute Medicine Rewind July 29, 2019
Chronic Disease

Maternal anemia in pregnancy may be associated with subsequent brain structure changes in offspring

December 5, 2022
Next Post
Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation

Wellness Check: Sleep

#VisualAbstract: Melanoma is projected to remain an important global health concern in 2040, with high incidence rates in fair-skinned populations of European descent

#VisualAbstract: Melanoma is projected to remain an important global health concern in 2040, with high incidence rates in fair-skinned populations of European descent

Racial, ethnic differences in outcomes of extremely preterm infants decreasing but persistent

Abnormal findings on neonatal cranial ultrasound associated with adverse neurobehaviour outcomes in neonates born prior to 30 weeks gestation

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options